Over $17 million in medical debt wiped out for Arizonans
PHOENIX, Feb. 5, 2025 /PRNewswire/ -- Every month across Arizona, thousands of people face a tough choice: Pay their medical bills or use that money to buy groceries or other essentials needed to get by.
Now, more than 12,000 people have less to worry about – thanks to the AZ Blue Foundation.
In the last two years, the Foundation has donated to Undue Medical Debt, which helped erase over $17 million in medical debt in Arizona. The AZ Blue Foundation plans to make another donation later this year to expand its impact in 2025. This is part of AZ Blue's continued effort to make healthcare easier and support health equity for all Arizonans.
"Provider bills can be a heavy burden," said Paul Penzone, Chief Community Relations Officer at AZ Blue. "Our gift helped ease some of that strain so people can focus on their health."
How AZ Blue made an impact
Each year, millions of Americans—more than 460,000 people across the state—find themselves needing unexpected surgeries or other critical care.
When the bills for these treatments arrive, people often feel they have nowhere to turn. In fact, they are three times more likely to struggle with depression or anxiety, the non-profit's research shows.
Here's how the program worked to help those who need it most:
Who provided the support?
The Blue Cross Blue Shield of Arizona Foundation for Community & Health Advancement (AZ Blue Foundation) in partnership with Undue Medical Debt
Debt Wiped Out:
The program wiped out medical debt across the state:
Yavapai County: all available debt for purchase in 2024
Maricopa County: $7.6 million
Pima County: $2.2 million
All 15 counties across Arizona benefited
Who qualified?
Families who earn 4X or below the poverty level.
Those with medical debt equal to 5% or more of their annual income.
On average, more than $1,600 in medical debt was forgiven per person in 2024. Learn more here about this effort.
ABOUT BLUE CROSS BLUE SHIELD OF ARIZONA
Blue Cross ® Blue Shield ® of Arizona (AZ Blue) is committed to helping Arizonans get healthier faster and stay healthier longer. With a mission to inspire health and make it easy, AZ Blue offers health insurance and related services to more than 2 million customers. AZ Blue, a non-profit company, is an independent licensee of the Blue Cross Blue Shield Association. The company and its subsidiaries employ more than 3,200 people in its Phoenix, Flagstaff, and Tucson offices. To learn more, visit azblue.com or connect with us on social media: Instagram, Twitter, LinkedIn or Facebook.
ABOUT THE BLUE CROSS BLUE SHIELD OF ARIZONA FOUNDATION FOR COMMUNITY & HEALTH ADVANCEMENT
The Blue Cross® Blue Shield® of Arizona Foundation for Community & Health Advancement invests in the health of Arizona by tackling mental health, substance use disorder, chronic health conditions, and health equity. A 501(c)(3) private, non-operating foundation, the Foundation works in service of the public good through grant funding for programs and applied research that align with its focus areas. The Foundation is an independent licensee of the Blue Cross Blue Shield Association. For more information, visit: azbluefoundation.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/over-17-million-in-medical-debt-wiped-out-for-arizonans-302369313.html
SOURCE Blue Cross Blue Shield of Arizona
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Medical debt can still appear on credit reports, judge rules
A federal judge blocked a rule from the Biden-era Consumer Financial Protection Bureau that would have kept medical debt from appearing on credit reports. Mind Your Money host Julie Hyman reports on the latest. To watch more expert insights and analysis on the latest market action, check out more Mind Your Money. A judge has blocked a Biden era ban on medical debt in credit reports. Now, technically, the rule from the Consumer Financial Protection Bureau never took effect, but if it had, it would have stopped medical bills from appearing on credit reports and barred lenders from using that data to make lending decisions. The CFPB says removing medical bill information could have wiped $49 billion off credit reports of about 15 million Americans and increased their credit scores by an average of 20 points. But a judge ruled in favor of two trade associations that argued the CFPB overstepped its authority in issuing that rule. This comes at a precarious time in health care, with millions of Americans expected to lose health insurance by 2034 due to changes in Medicaid under President Trump's new tax bill. So how does medical debt and your credit report work without this rule? Say you get medical care. The provider will send your bill to insurance, and you're responsible for whatever your insurance does not cover. If you don't pay that balance, the provider will likely send you reminders. If you still don't pay, they may send that debt to a collection agency. Once it's with the agency, they own that debt. They'll start calling and sending you letters, and they may report it to credit bureaus. Once reported, it can appear on your credit report. Now, it may not hurt your credit score right away. Medical debt must be one year old before it shows up on your credit report. Debt under $500 is not reported. And 14 states have provisions in place to remove medical collection debt from credit reports. But still, consumers are left with the responsibility to stay on top of changes to their credit as they face mounting bills.
Time Business News
2 hours ago
- Time Business News
Performance Meets Style: The Rise of Compression-Lined Swimwear
When it comes to swimwear, most people want something that looks good, feels comfortable, and moves with them—whether they're diving into the waves, lounging on a beach chair, or playing an intense game of beach volleyball. For decades, swim trunks were all about style, with performance often taking a backseat. However, a new wave of innovation has now transformed the way we think about beachwear. Enter compression-lined swimwear: a hybrid design that seamlessly marries style with athletic performance, giving wearers the confidence to move freely without compromising their appearance. This shift has redefined what it means to be beach-ready, and it's catching the attention of swimmers, surfers, and vacationers alike. In the past, swim trunks often came with a simple mesh lining—a design that, while functional, wasn't always the most comfortable. Anyone who has experienced chafing and awkward bunching knows the struggle. Over time, fabric technology evolved, and so did customer expectations. People wanted something that could handle a full day of activity while still looking stylish enough to wear straight from the shore to a seaside café. That's where compression-lined swimwear found its niche. By replacing flimsy mesh liners with soft, supportive compression shorts built into the swimwear, brands have created a piece that supports muscles, reduces irritation, and allows for more versatile wear. At first glance, compression-lined swimwear may appear to be any other pair of shorts. The secret is in the lining. Instead of the loose netting of traditional trunks, the interior features a layer of stretchy, breathable compression fabric that hugs the legs comfortably. Improved Comfort The snug fit of compression liners helps eliminate the uncomfortable rubbing and chafing caused by traditional mesh linings. This makes them perfect for long days at the beach or in the pool. Muscle Support Compression fabric is designed to support the muscles, reducing fatigue during activities like swimming, running, or paddleboarding. While the benefits may be more noticeable for athletes, even casual beachgoers enjoy the extra stability. Versatile Use One of the biggest advantages is that you can go from water to land activities without changing. Whether you're biking along the boardwalk or exploring a coastal trail, the built-in shorts offer sufficient coverage and support for a range of activities. Quick-Dry Technology High-quality compression-lined swimwear is often made from moisture-wicking materials, meaning they dry quickly after swimming. This makes them ideal for travel and spontaneous adventures. The modern beachgoer doesn't want to choose between looking good and feeling comfortable—they want both. Swimwear design has shifted to meet this demand, embracing bold prints, tailored fits, and technical fabrics all in one package. Compression-lined swimwear fits seamlessly into this new mindset. With sleek silhouettes and vibrant patterns, it's just as Instagram-ready as it is practical for a day of activity. This fusion of function and fashion is why so many people are making the switch. One of the main reasons compression-lined swimwear has risen in popularity is the growing interest in active lifestyles. Many people treat the beach as an outdoor gym, mixing swimming with workouts like beach runs, bodyweight exercises, or even yoga on the sand. This shift has prompted designers to create swimwear that can keep pace with the demands of these hybrid days. If you were browsing a lifestyle or fitness website, you'd likely notice a trend people are looking for gear that works harder for them. They don't want an outfit for each activity; they want one that adapts to them throughout the day. Compression-lined swimwear delivers exactly that. Choosing the right compression-lined swimwear depends on factors such as fit, fabric quality, style, and your level of activity. Look for a pair that feels snug but not restrictive. The compression liner should provide gentle muscle support without restricting circulation. If possible, try them on and move around to ensure the fit stays comfortable during activity. Premium fabrics will not only last longer but also maintain their shape and color after repeated exposure to saltwater, chlorine, and sun. Look for materials that offer both stretch and durability. From bold tropical prints to sleek solid colors, there's a design for every personality. Choose a style that you feel confident wearing, whether that's something understated or something that turns heads. If you plan to spend most of your time swimming laps, prioritize lightweight, hydrodynamic fabrics. If you'll be engaging in mixed activities—such as beach sports and casual walking—opt for a pair with a slightly looser outer shell for improved mobility. Compression-lined swimwear is just the beginning of performance-driven beach fashion. As textile technology advances, we can expect even more features—such as UV protection, temperature regulation, and eco-friendly fabrics made from recycled ocean plastics. These innovations are likely to make their way into everyday swimwear, further blurring the lines between athletic wear and leisurewear. Just as we've seen in the evolution of sneakers and sportswear, swimwear will continue to become more versatile, stylish, and sustainable. Eco-conscious consumers are already driving brands to find more sustainable ways to create compression-lined swimwear. By using recycled materials and adopting ethical manufacturing practices, companies are demonstrating that performance and style can coexist with environmental responsibility. The rise of compression-lined swimwear signals a new era where beachwear is no longer an afterthought but an essential piece of performance gear. It's proof that style and practicality can work hand in hand, making it easier than ever to enjoy both fashion and function in a single piece. Whether you're planning a beach vacation, training for a triathlon, or just looking for something comfortable to wear on a sunny afternoon, compression-lined swimwear offers a versatile solution. With the right pair, you can move with confidence, enjoy all-day comfort, and look great while doing it. In the end, this blend of innovation and design is more than just a trend—it's the future of swimwear. And for those who value both performance and style, it's a welcome change that's here to stay. TIME BUSINESS NEWS
